tradingkey.logo

enVVeno Medical Corp

NVNO
0.355USD
+0.013+3.74%
Close 12/24, 13:00ETQuotes delayed by 15 min
7.17MMarket Cap
LossP/E TTM

enVVeno Medical Corp

0.355
+0.013+3.74%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of enVVeno Medical Corp

Currency: USD Updated: 2025-12-24

Key Insights

enVVeno Medical Corp's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 211/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.50.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

enVVeno Medical Corp's Score

Industry at a Glance

Industry Ranking
211 / 404
Overall Ranking
379 / 4562
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Hold
Current Rating
12.500
Target Price
+1517.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

enVVeno Medical Corp Highlights

StrengthsRisks
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Overvalued
The company’s latest PE is -0.33, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.69M shares, decreasing 10.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 29.20K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.32.

Financial Health

Currency: USD Updated: 2025-12-24

The current financial score of enVVeno Medical Corp is 5.44, ranking 378/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
5.44
Change
0

Financials

2.04

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.39

Operational Efficiency

4.00

Growth Potential

6.75

Shareholder Returns

7.03

enVVeno Medical Corp's Company Valuation

Currency: USD Updated: 2025-12-24

The current valuation score of enVVeno Medical Corp is 6.35, ranking 299/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.33, which is -11.49% below the recent high of -0.29 and -1257.58% above the recent low of -4.47.

Score

Industry at a Glance

Previous score
6.35
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 211/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-24

The current earnings forecast score of enVVeno Medical Corp is 6.00, ranking 347/404 in the Biotechnology & Medical Research industry. The average price target for enVVeno Medical Corp is 12.50, with a high of 12.50 and a low of 12.50.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
12.500
Target Price
+1517.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
enVVeno Medical Corp
NVNO
1
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-24

The current price momentum score of enVVeno Medical Corp is 5.33, ranking 334/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.42 and the support level at 0.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.63
Change
0.7

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.032
Neutral
RSI(14)
41.909
Neutral
STOCH(KDJ)(9,3,3)
55.538
Buy
ATR(14)
0.039
Low Volatility
CCI(14)
79.186
Neutral
Williams %R
47.146
Neutral
TRIX(12,20)
-1.662
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
0.338
Buy
MA10
0.335
Buy
MA20
0.349
Buy
MA50
0.506
Sell
MA100
1.114
Sell
MA200
2.353
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-24

The current institutional shareholding score of enVVeno Medical Corp is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 28.14%, representing a quarter-over-quarter increase of 42.38%. The largest institutional shareholder is The Vanguard, holding a total of 861.19K shares, representing 4.26% of shares outstanding, with 24.31% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Perceptive Advisors LLC
1.28M
--
Kingdon Capital Management, L.L.C.
1.36M
+58.19%
The Vanguard Group, Inc.
Star Investors
698.34K
+16.21%
Westside Investment Management, LLC
279.52K
+7.90%
Geode Capital Management, L.L.C.
199.51K
+1.12%
J.P. Morgan Securities LLC
182.30K
-6.13%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-24

The current risk assessment score of enVVeno Medical Corp is 1.22, ranking 346/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.22
Change
0
Beta vs S&P 500 index
1.04
VaR
+6.60%
240-Day Maximum Drawdown
+94.02%
240-Day Volatility
+174.10%

Return

Best Daily Return
60 days
+12.79%
120 days
+22.95%
5 years
+27.47%
Worst Daily Return
60 days
-35.68%
120 days
-72.08%
5 years
-72.08%
Sharpe Ratio
60 days
-2.92
120 days
-2.25
5 years
-0.31

Risk Assessment

Maximum Drawdown
240 days
+94.02%
3 years
+95.28%
5 years
+97.03%
Return-to-Drawdown Ratio
240 days
-0.95
3 years
-0.33
5 years
-0.20
Skewness
240 days
-4.33
3 years
-2.88
5 years
-2.42

Volatility

Realised Volatility
240 days
+174.10%
5 years
+103.40%
Standardised True Range
240 days
+60.80%
5 years
+86.52%
Downside Risk-Adjusted Return
120 days
-201.35%
240 days
-201.35%
Maximum Daily Upside Volatility
60 days
+102.04%
Maximum Daily Downside Volatility
60 days
+111.12%

Liquidity

Average Turnover Rate
60 days
+4.51%
120 days
+2.50%
5 years
--
Turnover Deviation
20 days
+831.68%
60 days
+265.11%
120 days
+102.66%

Peer Comparison

Biotechnology & Medical Research
enVVeno Medical Corp
enVVeno Medical Corp
NVNO
5.00 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of enVVeno Medical Corp?

The TradingKey Stock Score provides a comprehensive assessment of enVVeno Medical Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of enVVeno Medical Corp’s performance and outlook.

How do we generate the financial health score of enVVeno Medical Corp?

To generate the financial health score of enVVeno Medical Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects enVVeno Medical Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of enVVeno Medical Corp.

How do we generate the company valuation score of enVVeno Medical Corp?

To generate the company valuation score of enVVeno Medical Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare enVVeno Medical Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of enVVeno Medical Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of enVVeno Medical Corp.

How do we generate the earnings forecast score of enVVeno Medical Corp?

To calculate the earnings forecast score of enVVeno Medical Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on enVVeno Medical Corp’s future.

How do we generate the price momentum score of enVVeno Medical Corp?

When generating the price momentum score for enVVeno Medical Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of enVVeno Medical Corp’s prices. A higher score indicates a more stable short-term price trend for enVVeno Medical Corp.

How do we generate the institutional confidence score of enVVeno Medical Corp?

To generate the institutional confidence score of enVVeno Medical Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about enVVeno Medical Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of enVVeno Medical Corp.

How do we generate the risk management score of enVVeno Medical Corp?

To assess the risk management score of enVVeno Medical Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of enVVeno Medical Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of enVVeno Medical Corp.
KeyAI